Home

BVF INVESTMENTS LLC

CIK 1132245 · last filed 2015-11-02

BVF INVESTMENTS LLC is a corporate insider who has filed 24 SEC Form 4 insider transactions across 10 companies since 2008. The most recent filing shows the insider sold $2.1M of CCXI on Nov 2, 2015. Across all open-market trades the lifetime net is +$163.7M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.79B across reported positions. The firm reports its address in San Francisco, CA. 264 SEC filings were submitted jointly with BVF INC/IL.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.79B

Companies

10

Total Filings

24

Lifetime Open-Market Net

$163.72M

Filer Profile

Reported Address
1 SANSOME ST
30TH FL
SAN FRANCISCO, CA 94104
Phone
(312) 506-6500
State of Incorporation
DE
Related Filers
BVF INC/IL — 264 joint filings, latest 2017-07-18
BVF PARTNERS L P/IL — 264 joint filings, latest 2017-07-18
BIOTECHNOLOGY VALUE FUND L P — 262 joint filings, latest 2017-07-18
BIOTECHNOLOGY VALUE FUND II LP — 259 joint filings, latest 2017-07-18
MARK N LAMPERT — 109 joint filings, latest 2017-07-18
LIGAND PHARMACEUTICALS INC — 33 joint filings, latest 2014-03-26
NEUROCRINE BIOSCIENCES INC — 31 joint filings, latest 2012-02-10
ARENA PHARMACEUTICALS INC — 11 joint filings, latest 2004-07-09
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CCXI 2,744,577 $12.32 $33.81M -$50.09M 3 2015-11-02
CBIO 16,323 $19.41 $316.8K $0 1 2015-08-21
LGND 248,144 $284.47 $70.59M $7.41M 3 2014-03-26
RIGL 112,385 $47.24 $5.31M -$7.68M 1 2013-11-20
Celera CORP (CRA) Delisted 34,656,684 — — $204.30M 2 2011-05-12
NBIX 10,257,894 $156.22 $1.60B -$2.39M 3 2010-04-13
FACT 7,671,129 $10.72 $82.23M $40.31M 2 2010-02-04
NEUROBIOLOGICAL TECHNOLOGIES INC /CA/ (NTII) Delisted 4,133,897 — — -$25.15M 1 2009-10-23
AVIGEN INC \DE (AVGN) Delisted 15,952,630 — — -$3.03M 3 2009-10-23
EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted 8,404,399 — — $56.2K 2 2008-11-26

Recent Filings

24 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2015-11-02 CCXI Sell (S) −300,000 -$2.09M EDGAR
2015-08-21 CBIO — — $0 EDGAR
2015-06-11 CCXI Sell (S) −5,734,200 -$51.61M EDGAR
2014-07-10 — Other (J) −2,964,552 -$13.52M
2014-03-26 LGND Sell (S) −469,356 -$32.90M EDGAR
2013-11-20 RIGL Sell (S) −2,907,732 -$7.68M EDGAR
2013-10-07 CCXI Buy (P) +656,550 $3.61M EDGAR
2011-08-10 LGND Buy (P) +3,598,200 $39.52M EDGAR
2011-05-12 Celera CORP (CRA) Delisted Buy (P) +21,537,600 $172.98M EDGAR
2011-04-11 Celera CORP (CRA) Delisted Buy (P) +3,843,750 $31.32M EDGAR
Showing 1–10 of 24
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.